المؤلفون: Sato, Hiroshi, Iba, Yutaka, Kawaharada, Nobuyoshi, Fukada, Joji, Iwashiro, Yuu, Tsushima, Shingo, Hosaka, Itaru, Okawa, Akihito, Shibata, Tsuyoshi, Nakazawa, Jyunji, Nakajima, Tomohiro, Hasegawa, Takeo, Tamiya, Yukihiko

المصدر: Interdisciplinary CardioVascular and Thoracic Surgery ; volume 36, issue 1 ; ISSN 2753-670X

الوصف: OBJECTIVES We analyzed the temperature in proximal aortic repair with moderate hypothermic circulatory arrest (HCA) and evaluated the effect of the cooling status on postoperative outcomes. METHODS A total of 340 patients who underwent elective ascending aortic replacement or total arch replacement with moderate HCA from December 2006 to January 2021 were studied. The change in body temperature trends recorded during surgery was shown graphically. Several parameters, such as the nadir temperature, cooling speed and the degree of cooling (cooling area), which was the area under curve of inverted temperature trends from cooling to rewarming as calculated by the integral method, were analyzed. The relationships between these variables and a major adverse outcome (MAO) postoperatively defined as prolonged ventilation (>72 h), acute renal failure, stroke, reoperation for bleeding, deep sternal wound infection or in-hospital death were evaluated. RESULTS An MAO was observed in 68 patients (20%). The cooling area was larger in the MAO group than in the non-MAO group (1668.7 vs 1383.2°C min; P < 0.0001). A multivariate logistic model showed that old myocardial infarction, peripheral vascular disease, chronic renal dysfunction, cardiopulmonary bypass time and the cooling area were independent risk factors for an MAO (odds ratio = 1.1 per 100°C min; P < 0.001). CONCLUSIONS The cooling area, which indicates the degree of cooling, shows a significant relationship with an MAO after aortic repair. This finding indicates that the cooling status with HCA can affect clinical outcomes.

الإتاحة: https://doi.org/10.1093/icvts/ivac282Test
https://academic.oup.com/icvts/article-pdf/36/1/ivac282/49286561/ivac282.pdfTest

المؤلفون: 長谷川, 武生, Hasegawa, Takeo

وصف الملف: PDF

الوصول الحر: https://ndlsearch.ndl.go.jp/books/R100000039-I12359122Test

Degree: 博士(医学) -- 札幌医科大学

المؤلفون: Matsumura, Yuki, Inomata, Sho, Yamaguchi, Hikaru, Mine, Hayato, Takagi, Hironori, Watanabe, Masayuki, Ozaki, Yuki, Yamaura, Takumi, Fukuhara, Mitsuro, Muto, Satoshi, Okabe, Naoyuki, Hasegawa, Takeo, Shio, Yutaka, Suzuki, Hiroyuki

المصدر: Thoracic Cancer ; volume 12, issue 15, page 2225-2228 ; ISSN 1759-7706 1759-7714

الوصف: Echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) rearrangements are found in ~ 5% of patients with non‐small cell lung cancer (NSCLC). Several tyrosine kinase inhibitors (TKIs) have been developed for treatment of so‐called ALK‐positive NSCLC. In cases of tumor progression during treatment with second‐generation ALK‐TKIs, such as alectinib, brigatinib, or ceritinib, National Comprehensive Cancer Network guidelines propose a switch to lorlatinib, a third‐generation ALK‐TKI, or to cytotoxic chemotherapy. However, they do not mention switching to other second‐generation ALK‐TKIs. Here, we present a rare case of a 53‐year‐old Japanese woman, who had never smoked, with ALK‐positive lung adenocarcinoma who survived alectinib‐resistant postoperative recurrence for 4 years by switching to ceritinib. She underwent curative resection for lung adenocarcinoma, but the cancer recurred at the bronchial stump and mediastinal lymph nodes. After platinum‐doublet chemotherapy, the patient still had a single growing liver metastasis, but the tumor was found to harbor EML4‐ALK rearrangement. Therefore, the patient started to take ALK‐TKIs. Alectinib was the second ALK‐TKI used to treat this patient. Alectinib shrank the liver metastasis, which was surgically resected. The tumor relapsed again during continued treatment with alectinib, which was switched to ceritinib. Ceritinib was effective for the relapsed tumor and treatment continued well for 4 years. This case report suggests that, in case of tumor progression during treatment with a second‐generation ALK‐TKI, switching to another second‐generation ALK‐TKI may be one of the treatment options. Further analyses are warranted to find robust markers to determine which ALK‐TKI is best for each patient.

الإتاحة: https://doi.org/10.1111/1759-7714.14058Test

المؤلفون: Watanabe, Masayuki, Higashi, Tomohito, Ozeki, Kana, Higashi, Atsuko Y., Sugimoto, Kotaro, Mine, Hayato, Takagi, Hironori, Ozaki, Yuki, Muto, Satoshi, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Shio, Yutaka, Suzuki, Hiroyuki, Chiba, Hideki

المساهمون: Japan Society for the Promotion of Science

المصدر: Scientific Reports ; volume 11, issue 1 ; ISSN 2045-2322

مصطلحات موضوعية: Multidisciplinary

الوصف: Malignant mesothelioma is a cancer with a poor survival rate. It is difficult to diagnose mesotheliomas because they show a variety of histological patterns similar to those of various other cancers. However, since currently used positive markers for mesotheliomas may show false positives or false negatives, a novel mesothelial positive marker is required. In the present study, we screened 25 claudins and found that claudin-15 is expressed in the mesothelial cells. We made new rat anti-human claudin-15 (CLDN15) monoclonal antibodies that selectively recognize CLDN15, and investigated whether CLDN15 is a good positive marker for malignant pleural mesotheliomas (MPMs) using MPM tissue samples by immunohistochemistry and semi-quantification of the expression level using an immunoreactive score (IRS) method. Of 42 MPM samples, 83% were positive for CLDN15. The positive ratio was equal to or greater than other positive markers for MPMs including calretinin (81%), WT-1 (50%), and D2-40 (81%). In 50 lung adenocarcinoma sections, four cases were positive for CLDN15 and the specificity (92%) was comparable with other markers (90–100%). Notably, CLDN15 was rarely detected in 24 non-mesothelial tumors in the tissue microarray (12/327 cases). In conclusion, CLDN15 can be used in the clinical setting as a positive marker for MPM diagnosis.

الإتاحة: https://doi.org/10.1038/s41598-021-91464-0Test
https://www.nature.com/articles/s41598-021-91464-0.pdfTest
https://www.nature.com/articles/s41598-021-91464-0Test

المؤلفون: Muto, Satoshi, Ozaki, Yuki, Inoue, Takuya, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Shio, Yutaka, Suzuki, Hiroyuki

المصدر: Case Reports in Oncology ; volume 14, issue 1, page 34-38 ; ISSN 1662-6575

مصطلحات موضوعية: Oncology

الوصف: Although diffuse cysts in the lung can be found in many diseases, they are uncommon in metastatic lung adenocarcinoma. They are even more unusual after the administration of immune checkpoint inhibitors. A case of lung adenocarcinoma that developed diffuse cysts in the lungs during treatment with nivolumab is reported. The patient was a 60-year-old woman with postoperative recurrent lung adenocarcinoma in mediastinal lymph nodes and pleural dissemination. After first-line treatment with cisplatin, pemetrexed, and bevacizumab, computed tomography (CT) showed disease progression. Treatment was then switched to nivolumab. After 5 courses of nivolumab, CT showed multiple ground-glass nodules in her lungs. After 4 more courses of nivolumab, the ground-glass nodules increased in size, and cystic air spaces appeared in their centers. The patient did not have any symptoms. Laboratory tests showed no evidence of infection or nivolumab-induced pneumonitis. Sialyl Lewis X-i antigen increased, and positron emission tomography showed abnormal uptake of 18 F-fluorodeoxyglucose in these lesions. Considering this evidence, the cystic lesions were diagnosed as multiple lung metastases. Various differential diagnoses should be considered when diffuse cystic lesions are found in the lungs after the administration of immune checkpoint inhibitors.

الإتاحة: https://doi.org/10.1159/000513426Test
https://www.karger.com/Article/Pdf/513426Test

المؤلفون: Takagi, Hironori, Zhao, Songji, Muto, Satoshi, Yokouchi, Hiroshi, Nishihara, Hiroshi, Harada, Toshiyuki, Yamaguchi, Hikaru, Mine, Hayato, Watanabe, Masayuki, Ozaki, Yuki, Inoue, Takuya, Yamaura, Takumi, Fukuhara, Mitsuro, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Osugi, Jun, Hoshino, Mika, Higuchi, Mitsunori, Shio, Yutaka, Kanno, Ryuzo, Aoki, Miho, Tan, Chengbo, Shimoyama, Saki, Yamazaki, Shigeo, Kikuchi, Hajime, Sakakibara-Konishi, Jun, Oizumi, Satoshi, Harada, Masao, Akie, Kenji, Sugaya, Fumiko, Fujita, Yuka, Takamura, Kei, Kojima, Tetsuya, Honjo, Osamu, Minami, Yoshinori, Nishimura, Masaharu, Dosaka-Akita, Hirotoshi, Nakamura, Koji, Inano, Akihiro, Isobe, Hiroshi, Suzuki, Hiroyuki

المساهمون: Japan Society for the Promotion of Science

المصدر: Lung Cancer ; volume 153, page 134-142 ; ISSN 0169-5002

الإتاحة: https://doi.org/10.1016/j.lungcan.2021.01.014Test
https://api.elsevier.com/content/article/PII:S0169500221000337?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0169500221000337?httpAccept=text/plainTest

المؤلفون: Hasegawa, Takeo Oku, Shoma Uchiya, Riku Okumura, Atsushi Suzuki, Iori Ono, Sakiko Fukunishi, Tomoharu Tachikawa, Tomoya

المصدر: Inorganics; Volume 11; Issue 7; Pages: 273

مصطلحات موضوعية: solar cell, guanidinium, cesium, first principles calculation, crystal structure, X-ray diffraction, polysilane, decaphenylcyclopentasilane

الوصف: The effects of guanidinium (C(NH2)3, GA) and cesium (Cs) co-additions on methylammonium lead iodide (CH3NH3PbI3, MAPbI3) perovskite solar cells were investigated. The first-principles calculations on the density of the states and band structures showed a reduction in the total energy by the GA addition. Although the calculation showed that the co-addition of the GA/Cs to the MAPbI3 perovskite could decrease the carrier mobilities, and the addition of GA/Cs improved the device performance. This result would be due to a facilitation of grain growth and a suppression of the defects from the GA/Cs addition. The changes to the conversion efficiencies of the device with the best performance were small, which indicates that the present co-addition of GA/Cs is effective for the stability of the devices.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=multidiscipl::2e5087f501830b410d70708b8a5c197cTest

المؤلفون: Muto, Satoshi, Ozaki, Yuki, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Shio, Yutaka, Hashimoto, Yuko, Suzuki, Hiroyuki

المصدر: Case Reports in Oncology ; volume 13, issue 3, page 1387-1392 ; ISSN 1662-6575

مصطلحات موضوعية: Oncology

الوصف: Large cell neuroendocrine carcinoma (LCNEC) of the lung with epidermal growth factor receptor ( EGFR ) mutation is rare, and few cases have been treated with EGFR tyrosine kinase inhibitors (TKIs). We report the treatment of combined LCNEC with adenocarcinoma harboring an EGFR mutation with EGFR-TKIs and bevacizumab. Our patient was a 70-year-old asymptomatic woman who underwent surgical resection of the lung for combined LCNEC with adenocarcinoma harboring an activating EGFR mutation 11 months previously. Magnetic resonance imaging (MRI) and positron emission tomography revealed metastatic lesions in the brain and lung. The patient was diagnosed with recurrence of combined LCNEC with adenocarcinoma. The brain lesion was irradiated, followed by administration of afatinib. Eight months after irradiation, brain MRI revealed ringed enhancement and perilesional edema after radiotherapy without new metastatic lesions. We switched treatment to erlotinib and bevacizumab, resulting in maintenance of stable disease for 10 months. Overall, the disease was controlled for 18 months with EGFR-TKIs and bevacizumab. Combination treatment with EGFR-TKIs and bevacizumab could be a treatment option for LCNEC of the lung harboring EGFR mutations, especially with brain metastasis.

الإتاحة: https://doi.org/10.1159/000511112Test
https://www.karger.com/Article/Pdf/511112Test

المؤلفون: Hasegawa, Takeo, Ozaki, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Fukuhara, Mitsuro, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki

المصدر: Journal of Medical Case Reports ; volume 13, issue 1 ; ISSN 1752-1947

مصطلحات موضوعية: General Medicine

الوصف: Background Immune checkpoint inhibitor therapy has changed the standard drug therapy for relapsed or advanced non-small cell lung cancer; its efficacy is well-recognized by pulmonary physicians, oncologists, and thoracic surgeons. Nivolumab, one of the anti-programmed cell death 1 antibodies, was the first immune checkpoint inhibitor to be approved and is used as a standard second-line regimen for patients with non-small cell lung cancer irrespective of the expression of programmed cell death ligand 1. Programmed cell death 1 antibodies have been generally confirmed to be less toxic than conventional cytotoxic chemotherapy, although unusual immune-related adverse events such as type I diabetes mellitus, adrenal failure, and myasthenia gravis may occur with a very low incidence. A case of severe grade V immune-related thrombocytopenia after two courses of nivolumab as second-line therapy for relapsed non-small cell lung cancer is reported. Case presentation An 82-year-old Japanese woman with relapsed lung adenocarcinoma was treated with nivolumab as second-line systemic therapy at our institute. Her laboratory data indicated thrombocytopenia suspected to be an immune-related adverse event following two courses of nivolumab. Subsequently, she developed a massive pulmonary hemorrhage and left cerebral infarction despite intensive treatment including systemic steroid therapy. Although there have been a few reports of thrombocytopenia caused by nivolumab, this is the first report of grade V thrombocytopenia following administration of nivolumab for relapsed non-small cell lung cancer. Conclusion A very difficult case of grade V immune-related thrombocytopenia after the administration of nivolumab as second-line therapy for relapsed lung adenocarcinoma was described. Immune-related thrombocytopenia is a rare adverse event, but it must be considered a possible complication because it may become critical once it has occurred.

الإتاحة: https://doi.org/10.1186/s13256-019-2245-yTest

المؤلفون: Owada-Ozaki, Yuki, Muto, Satoshi, Takagi, Hironori, Inoue, Takuya, Watanabe, Yuzuru, Fukuhara, Mitsuro, Yamaura, Takumi, Okabe, Naoyuki, Matsumura, Yuki, Hasegawa, Takeo, Ohsugi, Jun, Hoshino, Mika, Shio, Yutaka, Nanamiya, Hideaki, Imai, Jun-ichi, Isogai, Takao, Watanabe, Shinya, Suzuki, Hiroyuki

المصدر: Journal of Thoracic Oncology ; volume 13, issue 8, page 1217-1221 ; ISSN 1556-0864

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology

الإتاحة: https://doi.org/10.1016/j.jtho.2018.04.003Test
https://api.elsevier.com/content/article/PII:S1556086418305094?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1556086418305094?httpAccept=text/plainTest